

Press Release

Piramal Healthcare announces Q3FY2012 result

Total operating income up by 16% to ₹ 618 crores, Operating Profit was ₹ 37 crores and Net Profit for the quarter was ₹ 10 crores

Mumbai, 02 February 2012: Piramal Healthcare Limited ("PHL", NSE: PIRHEALTH, BSE: 500302) today announced Q3 results for FY2012.

Total operating income for the quarter was up by 15.5% to ₹ 617.6 crores. During the quarter, the R&D division of Piramal Life Sciences Limited (PLSL) has demerged into PHL. Due to the effect of demerger, the R&D expense of PLSL for nine months ended 31st December 2011 of Rs. 94.0 crores was booked in Q3 FY2012. PHL's investment of Rs. 2,856 crores to acquire 5.5% equity stake in Vodafone India Limited in August 2011 has resulted in interest/current income generating investments being replaced by Vodafone investment. As a result, Income from Investments was lower at Rs. 58.9 crores for Q3FY2012 as compared to Rs. 132.2 crores in Q3FY2011. Hence Operating Profit (OPBITDA) for the quarter was lower at ₹ 36.6 crores compared to Operating profit of ₹ 114.1 crores in Q3FY2011. The Operating profit margin for the quarter was lower at 5.9%. Net Profit for the quarter was ₹ 9.7 crores and EPS was ₹ 0.5 per share.

For Q3FY2012, Pharma Solutions (CRAMS) business registered strong growth of 57.4% with sales of ₹ 367.3 crores as compared to ₹ 233.4 crores in Q3FY2011. The revenues from Indian facilities grew by 68.9 % to ₹ 224.0 crores. The growth has been driven by increase in sales from Formulations and API generic businesses. Sale from facilities outside India also registered robust growth of 42.2% with sales of Rs. 143.3 crores. This growth has been driven by new early phase development business in Morpeth facility as well as from favorable currency movement.

Piramal Critical Care business recorded sales of Rs. 98.0 crores as compared to Rs. 99.4 crores in Q3 FY2011. OTC & Ophthalmology sales grew by 4.4% to ₹ 57.1 crores over Q3FY2011.

We have commenced operations of our Non Banking Finance Company – PHL Finance Pvt. Ltd. Income from Financial Services business which includes PHL Finance and IndiaReit Fund was Rs. 17.8 crores for the quarter.

9M FY2012 performance:

For continuing businesses, total operating income for 9MFY2012 was up by 26.1% to ₹ 1,664.3 crores. The Operating Profit for the nine months increased to ₹ 320.9 crores against ₹ 115.4 crores in 9MFY2011. The Operating profit margin was higher at 19.3% against 8.7% during 9MFY2011. Net Profit for the nine months was ₹ 152.6 crores and EPS was ₹ 9.0 per share.

Pharma Solutions business grew by 43.4% to ₹ 962.5 crores against ₹ 671.3 crores in 9MFY2011. The revenues from Indian facilities recorded strong growth of 74.8% to ₹ 583.8 crores over 9MFY2011 and the revenues from outside India facilities were Rs. 378.8 crores; up by 12.3%. Critical Care business recorded sales of Rs. 280.7 crores registering growth of 3.3%. OTC & Ophthalmology business grew by 32.4% to Rs. 169.8 crores.

For further information on the financials, please visit our website: www.piramalhealthcare.com

Note to the Editors:

About the Piramal Group

The Piramal Group, led by Ajay G. Piramal is one of India's foremost business conglomerates. Driven by the core values of Knowledge Action Care, the Piramal Group has interests in a myriad of industries that encompass healthcare, drug discovery & research, diagnostics, glass, real estate and financial services. The Piramal Group steadfastly pursues inclusive growth while adhering to ethical and value driven practices. The Group's turnover exceeded \$ 900 million in FY2011.

About Piramal Healthcare Ltd.

Piramal Healthcare is one of India's largest healthcare companies, with a growth track record of above 29% CAGR since 1988. Piramal Healthcare had consolidated revenues of \$ 650 million in FY2011. With assets across North America, Europe and Asia, Piramal Healthcare is also one of the largest custom manufacturing companies across the world. It has significant presence in the global critical space with sales of anesthesia products to over 100 countries. Recently, Piramal Healthcare has sold its domestic formulation business to Abbott for a consideration of US \$ 3.8 billion.

For investor enquiries, please contact:

Sagar Gokani / Prasad Mhatre Investor Relations Team, Piramal Healthcare Limited. Tel: +91 (0) 22 3046 6474 / 6489

investor.relations@piramal.com

For media enquiries, please contact:

PIRAMAL HEALTHCARE LIMITED PUBLIC RELATIONS AGENCY

Akansha Pradhan

Corporate Communications.

Piramal Group.

Contact: +91 22 3351 4082 akansha.pradhan@piramal.com

Tel: +91-22-6633 5969

Divya / Rakesh

Hanmer MS&L.

Mobile: +91 9769019059 / +91 9321735515

<u>divya.nair@hanmermsl.com</u> rakesh.reddy@hanmermsl.com